Durvalumab can be used, within its marketing authorisation, as an option to treat limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy in adults. Durvalumab can only be used if the company provides it according to the commercial arrangement.
What this means in practice
Durvalumab must be funded in the NHS in England for the condition and population in the recommendations, if it is considered the most suitable treatment option. Durvalumab must be funded in England within 90 days of final publication of this guidance.
There is enough evidence to show that durvalumab provides benefits and value for money, so it can be used routinely across the NHS in this population.
NICE has also produced tools and resources to support the implementation of this guidance.
Usual treatment for limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy is active monitoring (regular outpatient appointments and scans).
Clinical trial evidence shows that durvalumab increases how long people have before their condition gets worse and how long they live compared with active monitoring.
The cost-effectiveness estimates are within the range that NICE considers an acceptable use of NHS resources. So, durvalumab can be used.